ESRRA and breast cancer: Likewise, the mTOR-dependent stabilization of the metabolic regulator estrogen-related receptor alpha (ERRα) supports lapatinib resistance in HER2-amplified breast cancer by promoting the glutathione-dependent antioxidant capacity and enhancing glutamine dependency [14].